Guangdong Provincial People's Hospital

Other

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

115

Clinical Trials↗

All sponsored trials (all statuses)

Pipeline

Pipeline Snapshot

By Phase

12 drugs in development

Phase 31

Phase 24

Phase 13

Preclinical4

By Therapeutic Area

top 5

Oncology

533%

Neurology

17%

Immunology

17%

Nephrology

17%

Dermatology

17%

R&D Momentum

74/100

Pipeline Velocity

42/100

Trial Completion Rate

83/100

Pipeline Concentration

29/100

Pipeline Freshness

44/100

Strategic Signals

↗Early-stage heavy pipeline may seek late-stage partners
↗Active in Neurology but thin pipeline — potential licensing opportunity

Activity

Recent Activity

Last 14 days

Oct 27, 2026

Recruiting

A Phase II, Single-Arm, Single-Center Study of D-BACE in Combination With Chemotherapy and Camrelizumab for Resectable or Potentially Resectable II-IIIA or T3-4N2 Stage IIIB NSCLC

Oct 24, 2026

Recruiting

An Exploratory Phase II Clinical Study Protocol of Perioperative Treatment With Glesorasib Sequentially Combined With Ivonescimab and Chemotherapy for Resectable, Stage IB-IIIB, KRAS G12C-Mutant NSCLC

Earlier

Oct 1, 2026TrialEfficacy and Safety of Hyperbaric Oxygen Therapy in Improving Nab-paclitaxel-Induced Peripheral Neuropathy: A Randomized Clinical Trial

Sep 26, 2026TrialA Phase II, Multicenter, Randomized, Patient-Centered Study of the Efficacy and Safety of Immediate Local Consolidative Therapy (LCT) Versus Continued Immunotherapy Maintenance or Delayed Local Therapy (Non-LCT) After First-Line Chemoimmunotherapy in Metastatic NSCLC, Assessed by MDT

Sep 25, 2026TrialA Randomized, Multi-center, Open-label Phase II Trial of Irinotecan and Cetuximab With or Without the Combination of Bevacizumab and Sintilimab in RAS Wild-type, Irinotecan-refractory Metastatic Colorectal Cancer

Sep 15, 2026TrialASPIrin in Reducing Events in Dialysis

Sep 15, 2026TrialFficacy and Safety of Crisugabalin on Nociplastic Pain in Patients With Parkinson's Disease (RELIEF-PD): A Multicentre, Double-Blind, Randomised Controlled Trial

Sep 15, 2026TrialA Clinical Study on the Efficacy and Safety of Nalfurafine Hydrochloride Orally Disintegrating Tablets in the Treatment of Moderate to Severe Pruritus in Peritoneal Dialysis Patients

4 more events

Sep 15, 2026TrialCorrelation of Microbiome and Metabonomics With IgA Nephropathy

Sep 10, 2026TrialThrombus Aspiration in Primary Percutaneous Coronary Intervention for STEMI Patients With High Thrombus Burden

Aug 14, 2026TrialThe Effects and Neural Mechanisms of Vitamin D and Iron-Immune Homeostasis on Inhibitory Control in Obsessive-Compulsive Disorder

Aug 11, 2026TrialAn Exploratory Study to Evaluate the Safety and Efficacy of Universal STAR-T Cell Injection in Subjects With Autoimmune Kidney Diseases